Kantonsspital St.Gallen


Stefan Diem

Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Perez Shibayama C, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D E, Ludewig B, Levesque M P, Dummer R, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019; 7:50.
Diem S, Fässler M, Ali O H, Siano M, Niederer R, Berner F, Roux G A, Ackermann C J, Schmid S, Güsewell S, Früh M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
Gobba S, Moccia A A, Gulden-Sala W, Conconi A, Diem S, Cascione L, Iacoboni G, Margiotta-Casaluci G, Aprile von Hohenstaufen K, Stathis A, Hitz F, Pinotti G, Gaidano G, Zucca E. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions. Hematol Oncol 2017;.
Morganstein D L, Lai Z, Spain L, Diem S, Levine D, Mace C, Gore M, Larkin J. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 2017; 86:614-620.
Diem S, Hasan Ali O, Ackermann C J, Bomze D, Koelzer V H, Jochum W, Speiser D E, Mertz K D, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother 2017; 67:39-45.
Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews M C, Parakh S, Cebon J, Long G V, Carlino M S, Klein O. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 2016; 114:1084-9.
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44:51-60.
Diem S, Keller F, Rüesch R, Maillard S A, Speiser D E, Dummer R, Siano M, Urner-Bloch U, Goldinger S M, Flatz L, Diem S. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. J Immunother 2016; 39:379-382.
Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, Larkin J. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 2016; 114:256-61.
Diem S. Thyroid Abnormalities following the use of CTLA-4 and PD-1 Inhibitors in the treatment of melanoma. Clinical Endocrinology 2016;.
Richman J, Martin-Liberal J, Diem S, Larkin J. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert Opin Pharmacother 2015; 16:1285-97.
Diem S. Prognostic score for patients with advanced melanoma treated with ipilimumab. European Journal of Cancer 2015;.
Diem S. Diffuse large B-cell lymphoma in elderly patients: A retrospective analysis. European Journal of Internal Medicine 2014;.
Diem S. Off-Label use of anti-cancer drugs in switzerland: A population based prospective cohort study. European Journal of Clinical Pharmacology 2014;.
Diem S. Outcome of mantle cell lymphoma patients treated at a single institution over the past decade. Hematological Oncology 2013;.
page 1 of 1